Medical devices & pharma

Chargeback & Rebate Management for Medical Devices and Pharma

Contract pricing is negotiated with a GPO, delivered by a wholesaler, consumed by a member hospital, and reconciled by nobody. Chargebacks are where all three meet.

Book a demo For manufacturers

Eligibility is the entire control

A chargeback is valid only if that provider was entitled to that price on that date. Membership is effective-dated, which is why the check is so often skipped.

You
Channel partner
End customer
Your ledger
Value escapes here

1 Channel partner

GPO contract price agreed

Versioned by item and tier
2 End customer

Wholesaler sells to provider

At the contract price
3 Channel partner

867 sell-through reported

On the wholesaler’s cadence

A missing 867 period fails silently

silent gap in the basis
4 Channel partner

Chargeback claimed (844)
5 You

Eligibility checked

As of the SALE date, not today

Checked against a current roster, not history

30–60% unvalidated
6 Your ledger

Admin fee calculated

On the same sales basis

An invalid chargeback carries a fee on top of it

the error compounds

Closed: Membership, contracts and prices held as effective-dated history, so every line is judged against the world as it was on the sale date.

Two readings of the same problem

If you own the P&L, the left column is your version. If you own the systems, the right column is yours. Both have to be true for the fix to work.

The financial problem

You pay chargebacks against contract eligibility you cannot independently verify.

Wholesalers buy at list and sell to contracted providers at the GPO price, then charge back the difference. The volume is enormous and the eligibility check — is this provider actually a member entitled to this tier today — is the part that gets skipped.
GPO administrative fees are a percentage of contracted sales reported by the wholesaler. If the sales basis is overstated, the admin fee is overstated with it, and it compounds.
Tier eligibility changes as providers join, leave and merge. Chargebacks continue at the old tier after eligibility lapses, and recovery after the fact is commercially difficult.
Government pricing calculations depend on the same transactional net-price data. An error in the commercial chargeback stream is not just margin — it is a compliance exposure.

The technical problem

Membership, contract, chargeback and 867 data arrive from different parties on different calendars in different identifiers.

Provider identity spans DEA, HIN, 340B IDs and GPO member numbers, none of which are your customer master. Determining that a chargeback line refers to an eligible member requires resolving all of them.
GPO membership rosters arrive periodically and are effective-dated. Validating a chargeback requires knowing membership as of the sale date, not as of today — which means keeping history, not a current snapshot.
EDI 844/845/867 flows are high volume and format-sensitive. Rejected or partially loaded files create silent gaps in the sales basis used for admin fees and government pricing.
Contract price is versioned and effective-dated by item and tier. Reconstructing what price was valid on a given date for a given member is a query most systems cannot answer.

Benchmarks

What good looks like in medical devices & pharma

The numbers a well-run programme in this sector achieves. Treat any row you cannot answer as the finding.

Medical devices & pharma benchmarks
Metric	Typical today	Target
Chargeback lines validated against effective-dated eligibility	40 – 70%	>99%
Chargeback value disputed or corrected pre-payment	<1%	2 – 5% of submitted lines
Provider identifiers resolved to customer master	85 – 93%	>99.5%
867 sell-through files loaded without gaps	90 – 96%	100%, with alerting on any miss
Days to close contract-price net revenue	20 – 40 days	<5 business days

Ranges are indicative benchmarks drawn from published channel-incentive and pricing research together with our own implementation experience. They vary widely by programme complexity, channel depth and data quality — treat them as the opening question in a diagnostic, not a guarantee.

Eligibility is the entire control

A chargeback is only valid if, on the date of the sale, that provider was entitled to that contract price for that item. Everything else — the arithmetic, the file format, the settlement — is mechanical. Eligibility is the control, and eligibility is effective-dated, which is why it is so commonly not enforced.

Validating properly requires membership history rather than a current roster, provider identity resolved across several unrelated identifier systems, and a contract price versioned by item and tier. Systems that hold only the current state cannot answer the question at all, so the question stops being asked.

The fee that compounds the error

GPO administrative fees are calculated as a percentage of contracted sales, using sales data reported by the wholesaler. If that sales basis includes lines that should not have qualified, you pay a chargeback you did not owe and an admin fee on top of it. The two errors are correlated and both run in the same direction.

This is why chargeback validation is worth more than its face value in this industry: every dollar of invalid chargeback typically carries additional fee leakage behind it.

The compliance dimension

In pharmaceuticals the same transactional net-price data feeds government price calculations. That changes the nature of the problem: a chargeback control weakness is not only a margin issue but a reporting-accuracy issue with regulatory consequences. Which in practice means the audit trail matters as much as the arithmetic — you need to be able to demonstrate, line by line, why a given chargeback was accepted at a given price.

What good looks like

Above 99% of chargeback lines validated against effective-dated eligibility, not against a current roster.
Above 99.5% of provider identifiers resolved to your customer master across all identifier systems.
100% of 867 files loaded, with alerting on any gap — a missing file is a silent hole in both the chargeback basis and the admin-fee basis.

How RevUpra runs this

Membership, contracts and prices are held as effective-dated history rather than current state, so every chargeback line is evaluated against the world as it was on the sale date. Provider identifiers across DEA, HIN, 340B and GPO member numbers are resolved through the cross-reference engine to a single customer master record. 867 ingestion is monitored for gaps and alerts on a missing period rather than failing quietly. Admin fees are calculated from the validated sales basis, not the submitted one. And every acceptance decision carries an immutable trace, because in this industry the explanation is part of the deliverable.

Leak points

Where the money goes in this sector

Drawn from our nine-point taxonomy, ordered by how much they typically matter here.

Unvalidated channel claims

“You paid the claim because checking it cost more than the claim.”

Typical cost: 1.0% – 2.5% of channel revenue
Benchmark: A validated programme rejects or corrects 3–7% of submitted claim lines pre-payment.

How it closes: Every claim line is matched against its authorisation, price, window and entity before payment — and the exceptions, not the volume, go to a human.

See the module →

Identifier mismatch

“The match failed, so the money did not move.”

Typical cost: 0.4% – 1.5% of rebate-eligible revenue
Benchmark: Mature programmes hold unmatched transaction volume under 0.5% after cross-reference.

How it closes: A cross-reference engine reconciles partner, product and entity identifiers automatically, and every unmatched row is surfaced as work — not silently dropped.

See the module →

Contract drift

“You are operating a version of the deal nobody signed.”

Typical cost: 0.5% – 2.0% of contracted revenue
Benchmark: Best practice is zero drift — every executed term traceable to the clause that created it.

How it closes: The contract is the front door. Terms are mashed live from the deal, redlined with attribution, executed, and the executed version is what the engine runs.

See the module →

Accrual drift

“The liability on the balance sheet is not the liability you owe.”

Typical cost: 10% – 30% true-up variance at settlement
Benchmark: A transaction-level accrual holds settlement variance under 2%.

How it closes: Accruals are computed in-database from the transaction lines themselves, against locked accounting periods, and every posted number drills back to its source rows.

See the module →

Reporting latency

“By the time you saw the number, the quarter was over.”

Typical cost: 1 – 2 quarters of decision lag
Benchmark: Leading programmes see channel sell-through within 5 business days of period end.

How it closes: Materialised snapshots make financial reads instant, so channel performance is a screen you open — not a pack you wait for.

See the module →

See all nine leak points →

Terminology

The words this industry uses

Sector-specific language, defined — because a chargeback in pharma and a ship-and-debit in semiconductor are the same transaction with different names.

Chargeback ↗: The wholesaler's claim for the difference between the price they paid you and the contract price they sold at to an eligible provider.
GPO (group purchasing organisation) ↗: An organisation that negotiates contract pricing on behalf of member providers and collects an administrative fee on contracted sales.
Admin fee: A percentage of contracted sales paid to the GPO, calculated on sales data reported by wholesalers.
867 / sell-through ↗: The EDI transaction set in which a wholesaler reports what it sold, to whom — the basis for chargeback validation and admin fees.
Tier eligibility: Whether a specific provider qualifies for a specific contract price on a specific date, based on effective-dated GPO membership.

Open the full terminology library →

Programmes

What RevUpra runs for medical devices & pharma

Wholesaler chargeback validation against effective-dated membership
GPO contract price administration with versioned tiers
Administrative fee calculation and reconciliation
867 sell-through ingestion with gap detection
Provider identifier cross-reference across DEA, HIN and GPO member IDs

See this run against your own medical devices & pharma data.

The fastest way to size the opportunity is a diagnostic on one quarter of your real data — claims, purchases or sell-through. We will tell you what your actual rates are.

Book a demo Read the leak map